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moxetine treatment. CONCLUSIONS: At baseline, country-level variations in some
patient characteristics were evident in children with ADHD treated with atomox-
etine in the UK and IT. Further, this study suggests an opportunity for improved
ADHD treatment response and satisfaction outcomes.
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OBJECTIVES: To understand the association of antidepressant-related weight gain
with various aspects of worker productivity.METHODS: Employed individuals (18
years of age) with diagnosed depression (excluding bipolar disorder) completed a
web-based computer-generated 25-minute survey (study population identified by
Harris Interactive). Weight gain was measured using the Toronto Side Effects Scale
which measures medication-related side effects in the 2-weeks preceding the sur-
vey, and was analyzed as a 4-level ordinal variable (none, 2lbs, 4lbs, and
7lbs), where “none” was the referent category. The Work Productivity and Ac-
tivity Impairment (WPAI) questionnaire was used to assess percent of impaired
productivity (overall, absenteeism, presenteeism, activity impairment) during the
2-weeks preceding the survey, with higher numbers indicating greater impairment
and less productivity (i.e., worse outcomes). Using distribution among current an-
tidepressant users, each WPAI measure was categorized into quintiles, with the
lowest and highest representing least and greatest impairment, respectively. Cu-
mulative logit models were used to estimate the overall effect of weight gain on
WPAI measures as well as across gender. RESULTS: Of the 1521 survey respon-
dents, 872 (57%) reported current antidepressant use (60.6% female, mean age 49.9
 13.5 years). Weight gain was associated with loss of productivity: 2lbs (odds
ratio [OR] 1.54; p0.005),4lbs (OR 2.14 ; p0.0007 ) and7lbs (OR 2.96; p
0.0009). In females, using “no weight gain” as a reference group, the odds of being
in a worse overall productivity category increased with the increase of weight gain:
2lbs (odds ratio [OR]1.59; p0.02), 4lbs (OR2.17; p0.005) and 7lbs
(OR3.13; p0.01). Similar trends were observed in males: 2lbs (OR1.43;
p0.15),4lbs (OR2.00; p0.06) and7lbs (OR2.86; p0.02). CONCLUSIONS:
In employees with depression, antidepressant-related weight gain was associated
with loss in overall productivity. Additional research to quantify the indirect costs
of antidepressant-related weight gain in terms of productivity losses may be use-
ful.
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OBJECTIVES: Health care research in present scenario is a platform wherein a
range of interventions play their role to alleviate suffering and mitigate the course
of diseases. Gaming console have so far demonstrated promising and considerable
potential as rehabilitation and lifestyle treatments. The objective of this review
was to study the advent and role of new generation gaming consoles (e.g. Nintendo
Wii, Xbox, and PS3) in healthcare research in a systematic manner. METHODS: A
consolidated search strategy was developed and run in EMBASE, MEDLINE, Co-
chrane, POPLINE, SCOPUS, and Clinicaltrials.gov databases to identify the trials
utilising gaming consoles as principal intervention or supportive treatment in var-
ious disease areas. Grey literature was also identified though Google Scholar. Data
extraction was performed and results were summarized. RESULTS: The data re-
vealed that motion sensor and interactive gaming consoles have found their role in
multiple health care fields ranging from rehabilitation, weight loss, stroke recov-
ery, improvement in locomotor activity, Parkinson’s disease, Alzheimer’s disease,
and back pain, etc. Also, their active presence in promoting exercise, health care
coaching and monitoring, and health awareness programs has seen a marked
increase due to new and innovative applications being identified every day.
CONCLUSIONS: Newer health care technologies and platforms like gaming con-
soles help in numerous disease area to improve patient outcomes. Their transfor-
mation, propagation, and implementation as tools of healthcare services is a valu-
able strategy that the health care organizations should consider taking into
consideration the emerging field of gaming technology in parallel with health tech-
nology. Detailed analysis, data tables, and graphs describing the study results will
be presented.
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OBJECTIVES: Individuals with schizophrenia are found to receive poorer medical
care, and have a higher prevalence of diabetes than general population. Once a
hypoglycemic therapy is needed, proper compliance to the therapy and diabetic
care are important for achieving good glycemic control as well as preventing acute
complications. Therefore, this study aimed to compare diabetic care and risk of
acute complications after the initiation of the therapy for three years, between type
II diabetics with schizophrenia versus those without schizophrenia. METHODS:
This study used the claims database of the National Health Insurance program.
Enrollees who began oral hypoglycemic therapy in 2001, and had been diagnosed
with schizophrenia and refilled at least one prescription of antipsychotic(s) in the
year prior to the index date were included in the study (the case group). Enrollees
without schizophrenia who began oral hypoglycemic therapy in 2001 were selected
from a randomly selected sample of the enrollees to match the age and gender of
the case group (1:1) (the comparison group). Indicators of diabetic care included
good medication compliance (a medication possession ratio0.8), blood glucose
test, and HbA1c test. Indicators were measured annually. Acute complications
were defined as emergency room visits or hospital admissions due to coma, hypo-
glycemia, hyperglycemia, or diabetic ketoacidosis. Cox proportional hazards model
was adopted to assess risk of acute complications. RESULTS: There were 544 sub-
jects in the case group and comparison group, respectively. The percentage of
subjects compliant to the therapy in the case group was decreasing. In addition, the
case group had poorer blood glucose-related monitoring in the long run, and had a
higher risk of acute complications than the comparison group. CONCLUSIONS:
Diabetics with schizophrenia, compared with those without such a condition, had
worse diabetic care. Better disease management will be necessary for this patient
group.
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OBJECTIVES: Drug choice and adherence are important aspects in schizophrenia
and bipolar disorder (BD) and depend on patient and drug characteristics. Our aim
was to examine Nordic psychiatrists’ views on treatment choice, adherence, once
daily dosing (ODD), and the use of extended release (XR) and instant release (IR)
quetiapine.METHODS:We conducted a quantitative, telephone-based survey with
201 respondents randomly selected from a list of all 1906 Swedish and 677 Danish
psychiatrists (excluding child and geriatric psychiatrists). Structured, one-hour
qualitative interviews with 10 psychiatrists per country allowed us to further in-
terpret the results. Data was collected by an independent research company. For
binary variables, we performed a binomial test of the null hypothesis that the
alternative responses were equally likely. RESULTS: One hundred one Danish and
100 Swedish psychiatrists were included; 65% were male and the mean (SD) psy-
chiatric experience was 15.4 (8.2) years. No relevant country differences were
found. 198 psychiatrists (99%) agreed on the importance of individualized treat-
ment (p0.0001). Respondents reported that 42% of schizophrenia and 33% of BD
patients tried 3 antipsychotics before being stabilized. All respondents reported
non-adherence to be common and all associated non-adherence with side-effects.
199 (99%) psychiatrists thought that ODD would improve adherence (p0.0001),
and 196 (98%) that it could mitigate partial adherence problems (p0.0001). 179
respondents (89%) said that ODD reduces relapse rates (p0.0001). A total of 147
psychiatrists (73%) associated quetiapine XR with less day sedation than IR
(p0.0001), and 132 (66%) associated XR with a reduced need for injection treat-
ment (p0.0001). In the qualitative interviews, XR was to a higher extent associated
with antipsychotic monotherapy and IR more often with short-term use for e.g.,
sedation. CONCLUSIONS: Nordic psychiatrists considered individualized drug
therapies in schizophrenia and BD to be important and perceived ODD to improve
adherence. Respondents associated quetiapine XR with differential use compared
to IR.
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OBJECTIVES: This study was to estimate the national trend of physician-office
visits for patients with Alzheimer’s disease and senile dementia (ADSD), related
characteristics, primary payment source, and prescribed medications over a period
of 12 years (1998 – 2009) in the United States.METHODS: Physician-office visits with
ADSD diagnosis were identified in the National Ambulatory Medical Care Survey,
stratified by time frame, to perform a trend analysis for patients aged 40 with
relevant ICD-9-CM codes (290.xx, 294.xx, 331.xx). Main outcomes of interest are the
changes in ADSD physician-office visits, primary payer source, and prescribed
medications. A series of multivariate regressions (generalized linear model [GLM]
with Poisson distribution) for number of medications prescribed per visit were
employed by year to estimate the increased medication numbers associated with
ADSD, controlling for patient demographics, comorbidities, and visit/payment
characteristics. The impact of explanatory variables at both physician-office and
visit level was also assessed through hierarchical modeling. RESULTS: Over the
12-year period, the annual ADSD visits and average all-purpose medications pre-
scribed per ADSD visit have yearly growth rates of 18.2% and 10.7%, respectively.
Medicare has consistently been the largest primary payer for ADSD physician-
office visits (from 67% of visits in 1998 to 77% in 2009). Private payer and Medicaid
also have increased shares (from 6% to 13% and from 4% to 5%, respectively) as
primary payer, while fewer visit portions are primarily covered by Self-pay and
Other sources. Numbers of drug mentions per visit attributable to ADSD, esti-
mated through GLM regressions, are 0.64 in 1998, 1.92 in 2004, and 2.20 in 2009.
CONCLUSIONS: ADSD patients’ use of physician-office services has increased
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